Novel Anti-bacterial Activities of β-defensin 1 in Human Platelets: Suppression of Pathogen Growth and Signaling of Neutrophil Extracellular Trap Formation by Kraemer, Bjoern F. et al.
Novel Anti-bacterial Activities of b-defensin 1 in Human
Platelets: Suppression of Pathogen Growth and
Signaling of Neutrophil Extracellular Trap Formation
Bjoern F. Kraemer
1,2., Robert A. Campbell
1., Hansjo ¨rg Schwertz
1,3, Mark J. Cody
1, Zechariah Franks
1,
Neal D. Tolley
1, Walter H. A. Kahr
4, Stephan Lindemann
5, Peter Seizer
2, Christian C. Yost
1,6, Guy A.
Zimmerman
7, Andrew S. Weyrich
7*
.
1Molecular Medicine Program, University of Utah, Salt Lake City, Utah, United States of America, 2Medizinische Klinik III, Universitaetsklinikum Tuebingen, Tuebingen,
Germany, 3Department of Surgery, University of Utah, Salt Lake City, Utah, United States of America, 4Division of Haematology/Oncology, Program in Cell Biology,
Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada, 5The Petri-Hospital, Warburg, Germany, 6Department of Pediatrics,
University of Utah, Salt Lake City, Utah, United States of America, 7Department of Internal Medicine, University of Utah, Salt Lake City, Utah, United States of America
Abstract
Human b-defensins (hBD) are antimicrobial peptides that curb microbial activity. Although hBD’s are primarily expressed by
epithelial cells, we show that human platelets express hBD-1 that has both predicted and novel antibacterial activities. We
observed that activated platelets surround Staphylococcus aureus (S. aureus), forcing the pathogens into clusters that have a
reduced growth rate compared to S. aureus alone. Given the microbicidal activity of b-defensins, we determined whether
hBD family members were present in platelets and found mRNA and protein for hBD-1. We also established that hBD-1
protein resided in extragranular cytoplasmic compartments of platelets. Consistent with this localization pattern, agonists
that elicit granular secretion by platelets did not readily induce hBD-1 release. Nevertheless, platelets released hBD-1 when
they were stimulated by a-toxin, a S. aureus product that permeabilizes target cells. Platelet-derived hBD-1 significantly
impaired the growth of clinical strains of S. aureus. hBD-1 also induced robust neutrophil extracellular trap (NET) formation
by target polymorphonuclear leukocytes (PMNs), which is a novel antimicrobial function of b-defensins that was not
previously identified. Taken together, these data demonstrate that hBD-1 is a previously-unrecognized component of
platelets that displays classic antimicrobial activity and, in addition, signals PMNs to extrude DNA lattices that capture and
kill bacteria.
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Introduction
When bacteria enter the circulatory system, platelets are among
the first cells they encounter[1]. It is well known that bacteria
directly and indirectly induce platelet activation[2], but emerging
evidence indicates that platelets also alter the activity of bacteria
via the release of microbicidal proteins. Collectively, they are
termed platelet microbicidal proteins (PMPs), and include
chemokines, fibrinopeptides, and thymosin b-4[3]. Platelets deliver
PMPs to sites of infection where they exert direct antimicrobial
effects and potentiate the antibacterial properties of leuko-
cytes[3,4,5,6].
Whether PMPs represent the full repertoire of platelet
antimicrobial peptides is not known. Other cells use defensins to
counter invading bacteria[7]. Defensins are divided into a, b, h
family members that differ in structure, activity, and sites of ex-
pression[7]. Human a-defensins are very abundant in microbicidal
granules of polymorphonuclear leukocytes (PMNs) and Paneth
cells whereas b-defensins (hBD) are widely expressed in epitheli-
um[7,8,9,10,11,12]. This indicates that hBD’s serve as a first line
of innate defense against invasive pathogens[13]. Their primary
mode of action is to insert into cell membranes, which allows
hBD’s to permeabilize and kill bacteria[14]. In general, hBD-1 is
constitutively expressed while hBD’s 2-4 are induced in response
to infectious or inflammatory stimuli.
Other mechanisms of bacterial killing have recently been
identified, including the formation of neutrophil extracellular traps
(NETs) by PMNs[15]. NETs are lattices of DNA, histones and
granule enzymes that are released when stimulated PMNs
undergo a unique form of cell death[15,16]. These DNA-rich
NET complexes capture and kill bacteria. Platelets were reported
to induce NET formation by PMNs in sepsis[17]. The signaling
factors expressed by platelets that induce NET formation were not
identified, however.
PLoS Pathogens | www.plospathogens.org 1 November 2011 | Volume 7 | Issue 11 | e1002355Here, we explored mechanisms by which platelets directly kill
bacteria and, in parallel, actuate NET formation by PMNs. We
found that human platelets store hBD-1 in extragranular
compartments, identifying a previously unknown platelet antimi-
crobial factor. Platelets release hBD-1 when they are exposed to
lytic toxins and hBD-1 retards the growth of clinical strains of S.
aureus. In addition, we demonstrate for the first time that hBD-1
induces NET formation by human PMNs.
Materials and Methods
Ethics Statement
All studies were approved by the University of Utah
Institutional Review Board committee. Written informed consent
was provided by study participants and/or their legal guardians.
Platelet and Bacterial Interaction Studies
Platelets were freshly-isolated from human subjects as previously
described and exposed to CD45 positive selection, which
effectively depletes contaminating leukocytes[18,19]. The leuko-
cyte-depleted platelet preparations were resuspended in M199
culture medium.
Unless otherwise indicated, S. aureus were isolated from clinical
isolates of two sepsis patients and stored at 280uC. Twenty-four
hours prior to each study, a portion of the bacteria were expanded
on blood agar plates overnight at 37uC until they reached a
stationary growth phase. The bacteria were resuspended in
phosphate-buffered saline (PBS) and their concentration was
determined by colorimetry (VITEK Colorimeter, bioMerieux,
Inc., Durham N.C.). The S. aureus were then resuspended in M199
culture.
For each study, S. aureus (3610
7 total) was incubated in the
presence or absence of freshly-isolated platelets (1610
8/ml) for
four hours in M199 culture media unless otherwise indicated.
After this incubation period, which provided an environment for
exponential growth, the bacteria were serially diluted and 100 ml
of each dilution was plated on blood agar plates. The bacteria
were grown overnight at 37uC and the number of colony-forming
units (CFU’s) were counted the next morning.
In select studies, S. aureus was incubated in the presence of
recombinant hBD-1 (PeproTech, Rocky Hill, NJ) or hBD-1 that
was captured from platelet lysates. Recombinant hBD-1 was also
pre-incubated with an anti-hBD-1 antibody (Abnova, Taipei City,
Taiwan) or control IgG for 1 hour prior to being added to S.
aureus. Based on preliminary studies testing the effectiveness of the
anti-hBD-1 antibody in blocking hBD-1 induced NET formation,
a final concentration of 20 mg/ml was chosen for all studies.
For the capture of hBD-1, immunoprecipitates were prepared
from platelets (4610
9 total) that were lysed at 4uC in RIPA buffer
(1 x PBS, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS).
Insoluble cellular debri was cleared from the lysates by repeated
centrifugation (13,000 x G, 10 minutes) at 4uC. Cleared lysates
were incubated for 3 hours (4uC) with an antibody against hBD-1
(sc-20797, Santa Cruz Biotechnology, Santa Cruz, CA) or a
rabbit IgG control (sc-2027, Santa Cruz). The antibodies were
subsequently purified with protein A and G (A/G) coated agarose
beads (4uC, overnight). The A/G beads were then centrifuged,
pelleted, and washed with PBS. After 3 washes, immunoprecip-
itated proteins were eluted by adding 200 ml of glycine (100 mM,
pH 2.5) to the beads for 10 minutes followed by centrifugation and
isolation of the bead-free supernatant. The supernatant containing
the eluted proteins was neutralized (pH 7.2) with TRIS and then
incubated with S. aureus to measure growth as described above.
mRNA Expression Analyses
Megakaryocytes or platelets were lysed in Trizol Reagent
(Invitrogen, Carlsbad, CA) and RNA was extracted as previously
described[18,19]. Glycogen was added to the aqueous phase
before precipitation with isopropanol to optimize RNA yields. The
RNA was treated with DNAse (DNA free Kit, Ambion, Austin,
Texas), precipitated with ethanol, and dissolved in 12 mlo f
RNAse-free water. Identical isolation methods were used to isolate
RNA from HeLa cells, which served as a positive control for hBD
family members.
RNA (1 mg) from HeLa cells or platelets was used to generate
cDNA to characterize the expression of hBD-1, 2 and 3 using
procedures similar to those previously published[18,19]. Integrin
aIIb was used as a positive control for megakaryocyte and platelet-
specific RNA. The relative abundance of the defensin family
members was measured by real-time PCR. The specificity of
the amplicons for hBD-1, 2 and 3 was verified by agarose gel
electrophoresis and subsequent sequencing of the products. Primer
sets for these studies were as follows: hBD-1, forward-
GTCGCCATGAGAACTTCCTACC, reverse- CTGCGTCAT-
TTCTTCTGGTCAC; hBD-2, forward- GACTCAGCTCCT-
GGTGAAGCTC, reverse- ATGAGGGAGCCCTTTCTGAA-
TC; hBD-3, forward- CAGCGTGGGGTGAAGCCTAGCA,
reverse- TTTCTTCGGCAGCATTTTCGGC; and aIIb, for-
ward- ACACTATTCTAGCAGGAGGGTTGG, reverse- CAG-
GGCTCAGTCTCTTTATTAGGC.
Protein Expression Analyses
hBD protein expression was determined by immunocytochem-
istry and ELISA. The immunocytochemical studies were per-
formed as previously described in platelets that were fixed
immediately after they were isolated[20]. The intracellular pattern
of hBD-1 expression was determined as previously described[20]
using an antibody against hBD-1 (sc-20797; Santa Cruz) or its
control (rabbit IgG sc-2027; Santa Cruz). Wheat germ agglutinin
(WGA) (Alexa 555, Invitrogen), which stains granules and
membranes of platelets[20], or phalloidin (Alexa 488, Invitrogen)
was used as a counterstain.
To quantify hBD-1 protein levels, platelets were incubated with
vehicle or a variety of agonists that included thrombin (Sigma-
Aldrich, St. Louis, MO), thrombin receptor activating peptide
(TRAP, Sigma), platelet activating factor (PAF; Avanti Polar
Lipids, Alabaster, AL), Escherichia coli-derived lipopolysaccharide
(LPS; Invivogen, San Diego, CA) or S. aureus-derived a-toxin (List
Biological Laboratories, Campbell, CA). In select studies, platelets
were preincubated with taxol (Molecular Probes, Eugene, OR) or
nocodazole (Sigma) for 30 minutes prior to agonist stimulation
(Figure S4). At the end of the incubation period, intact platelets
were pelleted and lysed in RIPA buffer and the supernatants were
collected. Cell lysates and supernatants were added in duplicate to
commercially available ELISA plates specific for each of the
defensin family members (Alpha Diagnostics International, San
Author Summary
Platelets are small cells in the bloodstream whose primary
function is to stop bleeding. In addition to their clotting
functions, we show that human platelets stall bacterial
growth. This inhibitory property of platelets is due to b-
defensin 1, a small antimicrobial protein that kills bacteria.
b-defensin 1 also induces white blood cells to discharge
spider-like webs that trap and kill bacteria. Together, these
findings indicate that human platelets use b-defensin 1 to
fight off bacterial infection.
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also measured in platelet membranes and intracellular organelles
that were isolated by centrifugation of lysates on sucrose gradients.
Transmission Electron Microscopy
For the ultrastructural analyses, platelets and S. aureus were
cultured in suspension followed by fixation in 2.5% glutaraldehyde
in PBS buffer for at least 24 hours. The platelets and bacteria were
then washed with 0.1 M phosphate buffer (pH 7.4) followed by
dH2O by centrifugation at 800 x g (10 min). The samples were
postfixed with 2% osmium tetroxide (60 min), washed twice with
dH2O, dehydrated by a graded series of acetone concentrations
(50%, 70%, 90%, 100%; 2610 min each) and embedded in Epon.
Thin sections were examined with a JEOL JEM-1011 electron
microscope after uranyl acetate and lead citrate staining. Digital
images were captured with a side-mounted Advantage HR CCD
camera (Advanced Microscopy Techniques, Danvers, MA).
NET Formation
The basic protocol for isolating PMNs from whole blood and
imaging NETs was described in detail previously[16]. In brief,
PMNs (2610
6/ml) were placed on glass coverslips coated with
poly-L-lysine and incubated with recombinant hBD-1, hBD-2, or
hBD-3 or its vehicle for one hour at 37uC. In some experiments,
the recombinant defensins were pre-incubated with polymyxin B
(10 mg/ml) for 15 minutes at room temperature before addition to
PMNs. Recombinant hBD-1 was also pre-incubated with control
immunoglobulin or a neutralizing anti-hBD-1 antibody for one
hour before addition to PMNs. In addition, PMNs were incubated
with platelet proteins released from hBD-1 or IgG immunopre-
cipitates as described above. LPS was used as a positive control
for NET formation[16]. To examine the role of reactive o-
xygen species in hBD-1-dependent NET formation, PMNs were
pretreated (30 minutes) with diphenylene iodonium (DPI, 20 mM)
before addition of hBD-1. PMNs derived NETs were detected
with a non-cell permeable DNA dye (Sytox Orange, Molecular
Probes) while a cell permeable dye (Syto Green, Molecular Probes)
was used to visualize nuclei[16].
Quantification of Neutrophil Elastase Activity
PMNs (2610
6 cells /ml) in M199 were incubated at 37uCi n5 %
CO2/95% air with control buffer, LPS (100 ng/ml), or hBD-1
(100 ng/ml) for 60 minutes in a 24-well poly-L-lysine coated tissue
culture plate. NET-associated neutrophil elastase activity was
determined at selected time points as described[16].
Statistics
Using a minimum of three studies, we calculated the mean 6
standard error of the mean (SEM) for bacterial growth or hBD-1
protein levels for relevant figures. ANOVA’s were conducted to
identify differences among multiple experimental groups and if
differences existed, a Student Newman-Keuls post-hoc procedure
was used to determine the location of the difference. p,0.05 was
considered statistically significant.
Results
Platelets Encapsulate S. Aureus and Inhibit Its Growth
S. aureus expresses several proteins, such as clumping factor A and
fibronectin-binding protein A, that mediate aggregation and
activation of platelets [22,23,24]. Platelets also regulate the activity
of S. aureus. In particular, there is evidence that platelets inhibit the
growth of S. aureus[25,26]. To examine the potential inhibitory role
of platelets more closely, we incubated S. aureus with and without
unactivated human platelets. In the absence of platelets, S. aureus
grew uniformly in suspension culture over a four hour period
(Figure 1Aand 1B,leftpanels).Inthepresenceofplatelets,however,
S. aureus were encapsulated in discrete clusters that were surrounded
by platelets (Figure 1A–C). The majority of platelets in the culture
were vacuolated and many of the platelets were visibly lysed.
Although bacterial growth was noticeably impeded in the
presence of platelets (Figure 1B), S. aureus ingestion by platelets was
rare. Quantitative assessment demonstrated that platelets signifi-
cantly inhibited the growth of two strains of S. aureus growth that
were isolated from patients diagnosed with sepsis (Figure 2A–B
and Figure S1). Platelets did not inhibit the growth of common
laboratory strains of S. aureus (Figure S1). Likewise, the addition of
thrombin to the cultures did not enhance the inhibitory effects of
platelets on bacterial growth, which held steady for 8 hours but
relinquished after 24 hours (data not shown).
Platelets Express and Release b-defensin 1
Platelets release a variety of anti-microbial mediators, however
it is not known if defensins are part of this pool. Therefore, we
Figure 1. Platelets sequester S. aureus. Cultured S. aureus were
incubated in the presence or absence of platelets (240 minutes). At the
end of this period, an equal volume of fixative was added to the
suspension and the samples were prepared for confocal (A) or
transmission electron (B) microscopy. (A) The left panel shows S. aureus
(magenta - stained with topro-3) only. The middle panel displays the
pattern of S. aureus (magenta) growth in the presence of platelets,
which are not visible in this panel but shown in an overlay that is
displayed in the far right panel (bacteria, magenta; platelets, green –
stained with phalloidin). Scale bars=5 mm. (B) Transmission electron
microscopy of S. aureus in the presence (right panel) or absence (left
panel) of platelets. Scale bars=10 mm. (C) Differential interference
contrast (left panel) and transmission electron (right panel) microscopy
of clusters of S. aureus (arrows) surrounded by platelets. Scale
bars=5 mm. The panels in figure 1 are representative of three to four
independent experiments. Sa, S. aureus; P, platelets.
doi:10.1371/journal.ppat.1002355.g001
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member 1, but not 2 or 3 (Figure 3A). Precursor megakaryocytes
also contained mRNA for b-defensin family 1 (Figure S2).
Consistent with these findings, hBD-1 protein was readily detected
in quiescent platelets (Figure 3B and 3C).
hBD-1 distributed to platelet compartments that were distinct
from WGA staining of membrane regions (Figure 3B). We
previously showed that WGA also co-localizes with the a-granule
protein P-selectin[20]. Congruous with this staining profile, we
were unable to detect hBD-1 in granules that were purified by
subcellular fractionation (Figure S3). Furthermore, agonists that
induce a-granule secretion (i.e., thrombin, TRAP, or PAF) did not
appreciably elicit hBD-1 release from platelets (Figure 3C). We
also found that microtubules, which modulate a-granule secre-
tion[27], remained intact in platelets that were co-incubated with
S. aureus (Figure S4A). Interruption of microtubular function with
taxol or nocodazole in platelets had no effect on hBD-1 release in
response to a-toxin, a pore-forming exotoxin that is derived from
S. aureus (Figure S4B). Similarly, inhibition of microtubular
function did not prevent platelets from limiting the growth of
S. aureus (next section and Figure S4C).
Platelet-derived b-defensin 1 Impedes the Growth of
S. Aureus
We determined if platelet-derived hBD-1 inhibits bacterial
growth, an activity reported for recombinant hBD1. As expected,
we found that recombinant hBD-1 retards S. aureus growth over a
4-hour period (Figure 4A). Similar inhibitory responses were
observed when hBD-1 was captured from platelets by immuno-
precipitation and then incubated with S. aureus (Figure 4B). In
contrast, there was no inhibition by a control immunoglobulin
immunoprecipitates (Figure 4B).
Figure 2. Platelets impede the growth of S. aureus. Cultured
S. aureus were incubated in the presence or absence of platelets for 240
minutes and bacterial growth was then measured as described in
Materials and Methods. (A) The blood agar plates are representative
examples of four independent studies. (B) The bars in the lower panel
represent the mean6SEM of the fold increase in S. aureus growth (240
minutes) in the presence or absence of platelets over baseline
(horizontal line). The single asterisk indicates a significant increase
(p,0.05) in growth over baseline. The double asterisks indicates a
significant (p,0.05) reduction in S. aureus growth in the presence of
platelets when compared to S. aureus growth by itself.
doi:10.1371/journal.ppat.1002355.g002
Figure 3. Platelets express and release b-defensin 1 in response
to a-toxin. (A) The curves show real-time PCR results for integrin aIIb
and each of the defensin family members in platelets using the same
template RNA. The inset shows semi-quantitative PCR for hBD-1, -2 and
-3 in platelets and HeLa cells. This figure is representative of three
independent experiments. (B) Immunocytochemical analysis of hDB-1
(green) and WGA in unstimulated platelets. Inset (top row, hBD-1): area
selected for enlargement and merge. This figure is representative of five
independent experiments. Scale bars=5 mm. (C) hBD-1 protein in
lysates and supernatants from platelets that were stimulated with a-
toxin (50 ng/ml), thrombin (0.1 U/ml), TRAP (20 mM), or PAF (100 nM)
for 30 minutes. The bars represent the mean6SEM of three
independent experiments.
doi:10.1371/journal.ppat.1002355.g003
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growth, platelets were pre-incubated with a neutralizing anti-hBD-
1 antibody or control immunoglobulin before the addition of
bacteria. In these studies, platelets had a significantly reduced
capacity to limit the growth of S. aureus in the presence of the hBD-
1 neutralizing antibody (Figure 4C).
b-defensin 1 Induces NET Formation by PMNs
We next asked if hBD-1 has novel antimicrobial activities and
focused on the formation of NETs, a defensive function used by
PMNs to trap and kill microbes in the extracellular milieu[16]. We
first examined if platelet-derived hBD-1 could induce NET
formation. hBD-1 harvested from platelet immunoprecipitates,
but not control immunoprecipitates, induced robust NET
formation (Figure 5A). Consistent with this finding, recombinant
hBD-1 induced NET formation (Figure 5B). A neutralizing anti-
hBD-1 antibody, but not control immunoglobulin, blocked hBD-1
dependent NET formation (Figure 5B) while having no effect on
LPS-induced NET formation (data not shown). Unlike hBD-1,
hBD-2 and hBD-3 did not induce appreciable NET production
over a spectrum of concentrations (Figure 6 and data not shown).
Inhibition of NADPH oxidase activity, a critical enzyme in the
formation of reactive oxygen species (ROS), blocked LPS and
hBD-1 induced NET formation compared to controls (Figure 7A).
Polymyxin B, however, did not alter hBD-1 induced NET
formation indicating that the effect of hBD-1 was not due to
residual LPS contamination in the hBD-1 preparation (data not
shown). Finally, hBD-1 significantly increased neutrophil elastase
activity in the absence of appreciable cell death (Figure 7B and
7C).
Discussion
In this report we show that platelets express hBD-1 that localizes
to extragranular regions within the cell and is discharged into the
supernatant in response to bacterial toxins. Platelet-derived hBD-1
directly inhibits the growth of strains of S. aureus isolated from
patients with sepsis, suggesting that platelets may use hBD-1 to
limit the growth of other bacteria as well. Moreover, hBD-1
induces PMNs to extrude NETs, identifying a new function of
defensins in host defense. Together, these findings provide new
insights into the antibacterial activity of platelets and establish a
mechanism by which platelets may trigger NET formation.
Although NET formation likely contributes to pathogen contain-
ment in humans, it is possible that under certain circumstances (i.e.
clinical deterioration) it can lead to potentially deleterious
pathologic platelet-leukocyte interactions in sepsis[17].
Mammalian defensins are small cationic peptides that have
activity against a broad range of pathogens[7]. a-defensins are
abundant in the microbicidal granules of PMNs and defensin
alpha 1, also known as human neutrophil peptide-1, has been
detected at the mRNA level by gene expression profiling in
megakaryocytes[28]. b-defensins are generally present in skin and
mucosal epithelia. b-defensins are phylogenetically older and new
family members continue to be identified, with approximately 40
potential coding regions on the human genome[13]. hBD-1 was
the first b-defensin discovered [29]. Although hBD-1 expression is
primarily restricted to epithelium, it has been detected in
peripheral blood [30] and was originally isolated from plasma
filtrates of patients with end stage renal disease [29]. Here, we
demonstrate that platelets express and release hBD-1 protein in
response to S. aureus-derived toxins. Platelets have also recently
been shown to express and release hBD-3 protein[31]. Interest-
ingly, our data suggest that platelets may accumulate hBD-1 and
hBD-3 protein through distinct mechanisms. In this regard, we
detected mRNA for hBD-1 in precursor megakaryocytes and
platelets suggesting that megakaryocytes transfer hBD-1 protein to
platelets during thrombopoiesis. We did not, however, detect
hBD-3 mRNA in platelets under the conditions of our exper-
iments. This suggests that platelets may endocytose hBD-3 as they
Figure 4. Platelet-derived b-defensin 1 inhibits the growth of S. aureus. (A) S. aureus growth was determined in the presence of recombinant
hBD-1 (400 ng/ml) or its vehicle. The bars represent the mean6SEM of the fold increase in S. aureus growth (240 minutes) over baseline (horizontal
line). The single asterisk indicates a significant increase (p,0.05) in growth over baseline. The double asterisks indicates a significant (p,0.05)
reduction in S. aureus growth in the presence of recombinant hBD-1 when compared to S. aureus incubated with its vehicle. (B) S. aureus growth in
the presence of immunoprecipitates that were captured from platelet lysates incubated with anti-hBD-1 or its control IgG. The bars represent the
mean6SEM of the fold increase in S. aureus growth (240 minutes) over baseline (horizontal line). The single asterisk indicates a significant increase
(p,0.05) in the growth of S. aureus that was treated with IgG immunoprecipitates over baseline. The double asterisks indicates a significant (p,0.05)
reduction in S. aureus growth in the presence of anti-hBD-1 immunoprecipitates when compared to IgG immunoprecipitates. (C) The growth of
S. aureus in the absence or presence of platelets that were co-incubated with a neutralizing antibody against hBD-1 or its IgG control. The bars
represent the mean6SEM of the fold increase in S. aureus growth (240 minutes) over baseline (horizontal line). The single asterisk indicates a
significant increase (p,0.05) in the growth of S. aureus alone or S. aureus co-incubated with platelets and anti-hBD-1 over baseline. The double
asterisks indicates a significant (p,0.05) reduction in S. aureus growth in the presence of platelets incubated with control IgG when compared to S.
aureus alone or S. aureus co-incubated with platelets and anti-hBD-1.
doi:10.1371/journal.ppat.1002355.g004
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Tohidnezhad and colleagues detected significant amounts of hBD-
3 protein in plasma and platelets [31].
Unlike b-defensins 2–4, hBD-1 is constitutively produced by
most epithelial cells[7,8,9]. It has also been detected in
keratinocytes[32]. Thus, hBD-1 is positioned and ready to mediate
innate host defense against pathogens in the gut, respiratory tract,
oral cavities, and skin[7,32,33]. Megakaryocytes invest platelets
with hBD-1 mRNA and hBD-1’s basal protein expression in
platelets indicates that it may also serve critical functions in defense
against pathogens that gain access to the bloodstream. Platelets are
immediate responders and the most abundant cell type to
accumulate at sites of intravascular infection, which include
infective endocarditis, suppurative thrombophlebitis, mycotic
aneurysm, septic endocarditis, catheter and dialysis access site
infections, and vascular prosthesis and stent infections[1,2,3].
Sequestration of bacteria and localized release of hBD-1 and other
microbicidal proteins by platelets may limit the growth of
pathogens at infected areas, providing time for leukocytes to
gather and kill remaining bacteria.
S. aureus is one of the most common pathogens encountered by
humans and a primary cause of infective endocarditis[2]. Our
studies show that when platelets contact S. aureus, they encircle the
pathogen and force it into encapsulated clusters. This may entrap
and sequester the bacteria, reducing or preventing intravascular
dissemination. The surrounding platelets are structurally altered, as
evidenced by empty vacuoles. While hBD-1 is released under these
conditions, our studies suggest that the mechanism is distinct from
traditional secretory pathways in platelets since the defensin is
basally localized in submembrane cytoplasmic domains rather than
granules. In this regard, circumferential bands of microtubules are
readily detected beneath the plasma membranes of platelets (Figure
S3 and data not shown). This implies that S. aureus induces hBD-1
release by a mechanism that is distinct from granule secretion which
is accompanied by microtubule reorganization, possibly by directly
forming pores in platelet membranes. Indeed, some platelets were
visibly lysed by S. aureus, which is perhaps a terminal event that
discharges intracellular contents, including hBD-1, into the
extracellular milieu. Furthermore, we found that a-toxin, which
forms pores in cell membranes, evoked hBD-1 release by platelets in
a microtubule-independent fashion while receptor-mediated ago-
nists (i.e., thrombin, TRAP, or PAF) that typically induce a-granule
secretion did not induce release of the defensin. Extragranular
storage may guard against inappropriate release of hBD-1, which
could haveunwarranted cytotoxicity. Similar expression and release
patterns are observed in epithelial cells, where hBD-1 is secreted
independent of degranulation[33].
As part of the response to infection, host cells often internalize
and kill bacteria. Thrombin-activated platelets are reported to
Figure 5. b-defensin 1 induces NET formation by PMNs. (A) NET
formation in the presence of control immunoglobulin (left panel) or
hBD-1 (right panel) immunoprecipitates that were captured from
human platelets. The NETs (arrows) were detected by live cell imaging
as previously described[16]. (B) NET formation in untreated PMNs
(control) or PMNs incubated with 100 ng/ml of recombinant hBD-1
alone or in the presence of anti-hBD-1 or its control IgG. Figure 5A and
5B are representative of three independent experiments.
doi:10.1371/journal.ppat.1002355.g005
Figure 6. b-defensin 1, but not other b-defensin family
members, induce PMNs to form NETs. PMNs were left untreated
(control) or incubated with 100 ng/ml of recombinant hBD-1, hBD-2, or
hBD-3. After 60 minutes, NETs (arrows) were detected by live cell
imaging as previously described[16]. Increasing concentrations of hBD-
2 or hBD-3 failed to induce NET formation (data not shown). Images are
representative of three independent experiments.
doi:10.1371/journal.ppat.1002355.g006
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killing chambers like PMNs and macrophages[36]. Internalization
of S. aureus by platelets was rare under the conditions of our
experiments (data not shown) and inhibition of platelet microtu-
bule function, which facilitates S. aureus uptake in other cells[37],
did not affect bacterial growth. This suggests that platelets limit
S. aureus growth by quarantining the bacteria and locally releasing
a variety of microbicidal proteins. Additional studies are required
to determine if platelets display similar activities against S. aureus in
more complex milieus that contain plasma and other cells. It will
also be important to decipher why platelets limit the growth of
clinical, but not laboratory, strains of S. aureus. In this regard,
phenotypic and genotypic characterization of persistent S. aureus
and determination of virulent signatures, which may or may not
induce hBD-1 release from platelets, will be particularly
informative.
To date, there are five distinct lineages of platelet microbicidal
proteins (PMPs) that include: 1, platelet factor 4 and variants; 2,
platelet basic protein and its proteolytic derivatives connective
tissue activating peptide-3 and neutrophil activating peptide-2
(NAP-2); 3, regulated upon activation normal T cell expressed and
secreted (RANTES); 4, thymosin b-4; and 5, fibrinopeptides
[3,6,38]. In some cases, PMPs are cleaved into their active form by
thrombin or other proteases in the immediate vicinity [3]. When
platelets become activated they express surface P-selectin, which
binds neutrophils, and release constitutively stored PMPs. Both
platelet-neutrophil complexes and PMPs exert anti-microbial
activity[6,38,39].
a-toxin induces the release of PMPs that possess staphylocidal
activity [40]. Similarly, we demonstrate that platelets release hBD-
1 in response to a-toxin indicating that hBD-1 is readily releasable
from a cytoplasmic platelet compartment. PMPs and hBD-1 may
have cooperative antibacterial activities. Like PMPs, we found that
hBD-1 purified from platelets is capable of inhibiting the growth of
S. aureus. PMPs permeabilize bacterial membranes in what appears
to be a voltage-dependent manner[3] while defensins insert into
Figure 7. b-defensin 1 mediated NET formation is dependent on reactive oxygen species. (A) PMNs were incubated with diphenylene
iodonium (DPI) and then left untreated (control) or stimulated with 100 ngl/ml of LPS or hBD-1 for 1 hour. Images are representative of three
independent experiments. (B) PMNs were left alone or treated with 100 ng/ml of LPS or recombinant hBD-1 for 1 hour and then stained with trypan
blue to determine cell viability. (C) PMNs were left alone or incubated with 100 ng/ml of LPS or recombinant hBD-1. After 1 hour, neutrophil elastase
activity was measured. The bar graph represents the percent increase in neutrophil elastase activity over untreated neutrophils. The bars in panel B
and C represent the mean6SEM of three independent experiments.
doi:10.1371/journal.ppat.1002355.g007
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activation of lytic enzymes that permeabilize lipid bilayers[14].
Their precise modes of action at the bacterial cell wall, however,
may not overlap completely. In side-by-side comparisons, Yeaman
and colleagues [41] demonstrated that PMPs and neutrophil a-
defensins disrupt S. aureus cytoplasmic membranes by distinct
mechanisms. If the same holds true for b-defensins, PMPs and
hBD-1 may attack bacteria from separate vantage points
influencing the susceptibility of different bacterial strains to
platelets. It is also possible that hBD-1 inhibits bacterial activity
by cooperating with other factors that are yet to be identified. This
notion is supported by the fact that neutralization of hBD-1
activity was only partially protective in preventing platelets from
inhibiting bacterial growth.
It has been suggested that defensins have other functions besides
direct microbial killing. Neutrophil-derived a-defensins modulate
agonist-induced platelet aggregation and secretion[42]. b-defen-
sins are chemotactic for monocytes, macrophages and dendritic
cells[7,43] and have been shown to differentially regulate the
expression of numerous cytokines in human mononuclear
cells[44]. Specifically, hBD-1 induces the expression of interleukin
8 and monocyte chemotactic protein-1[44]. It is well appreciated
that platelets induce expression and other inflammatory gene
products[45,46]. Whether or not platelet-derived hBD-1 influenc-
es chemokine synthesis in target leukocytes is not known. Here, we
show for the first time that hBD-1, but not other hBD family
members, induces NET formation by PMNs, demonstrating an
antimicrobial activity distinct from direct killing that amplifies the
antibacterial properties of PMNs. NETs are web-like DNA
structures that trap and kill bacteria. The DNA backbones of
NETs are studded with histones, neutrophil elastase, myeloperox-
idase, and bactericidal permeability increasing protein that
together can degrade virulence factors and kill ensnared
pathogens[15]. Although we demonstrate that platelet-derived
hBD-1 induces NET formation, additional work is needed to
dissect the exact roles of hBD-1 in eliciting NET formation by
platelets that contact PMNs in human diseases such as sepsis.
Previous studies have shown that LPS stimulated platelets induce
PMNs to form NETs through mechanisms that remain unclear
[17] [47]. Although hBD-1 may be involved in this process, LPS
alone does not directly induce hBD-1 release by platelets (Figure
S5). This suggests that multiple factors, or more potent lytics such
as a-toxin, may be required to trigger hBD-1 release from platelets
that subsequently stimulates NET formation by PMNs. Human
BD-1 may also work in concert with S. aureus, which has recently
been shown to directly induce NET formation by PMNs[48].
In summary, hBD-1 is basally expressed and released by
platelets exposed to a-toxin. It is likely that hBD-1 cooperates with
other PMPs to influence bacterial activity and growth, although
their release patterns and potency against bacteria may be distinct
from one another. By itself, hBD-1 directly inhibits the growth of
gram-positive bacteria. Further, it has the novel capacity to
engender PMNs to form NETs. The binary actions of hBD-1 are
likely to play important roles in sepsis and other infectious diseases
where platelets and neutrophils work together to trap, kill, and
clear invading pathogens.
Supporting Information
Figure S1 Platelets impede the growth of clinical S.
aureus strains. Platelets were incubated with two laboratory
strains of S. aureus or two strains of S. aureus (one non-methicillin
resistant and one methicillin resistant) isolated from patients
diagnosed with sepsis. The bars represent the mean6SEM (n=3)
of the fold increase in S. aureus growth (240 minutes) over baseline
(horizontal line). The single asterisk indicates a significant increase
(p,0.05) in growth over baseline. The double asterisks indicates a
significant (p,0.05) reduction in S. aureus growth in the presence of
platelets when compared to S. aureus growth by itself.
(EPS)
Figure S2 Megakaryocytes express b-defensin 1 mRNA.
The curves show a representative real-time PCR result for integrin
aIIb and hBD-1 in megakaryocytes and platelets. The table below
the figure identifies the Ct values for integrin aIIb and hBD-1 from
two megakaryocyte cultures.
(TIF)
Figure S3 b-defensin 1 is located in an extragranular
compartment in platelets. Platelets were exposed to nitrogen
cavitation and their organelles (i.e., mitochondria and granules),
membranes, and remaining cytosolic constituents were separated
by sucrose gradients as previously described[49]. Each compart-
ment was subsequently lysed in RIPA buffer and hBD-1 levels
were determined. This graph is representative experiment of two
independent studies.
(EPS)
Figure S4 The antibacterial activities of b-defensin 1 are
not dependent on microtubular reorganization. (A) High
resolution electron micrograph of a platelet that was co-incubated
with S. aureus. The platelet ultrastructure is preserved with an
intact microtubule coil (white arrow) and the absence of platelet
projections, however, the platelet displays other features of
activation that include increased vacuoles (black arrow). Scale
bar=1 mm. This micrograph is representative of numerous other
platelets. (B) hBD-1 protein in platelet lysates and supernatants
that were stimulated with a-toxin (50 ng/ml) in the presence of
Taxol (50 mM), Nocodazole (Nocod; 10 mM), or their vehicle
(control) for 30 minutes. The bars represent the mean6SEM of
three independent experiments. (C) S. aureus was cultured for 240
minutes (gray bars) in the presence or absence of platelets that
were pretreated with Taxol (50 mM) or Nocodazole (Nocod;
10 mM). The bars in the panel represent the mean6SEM (n=3) of
the fold increase in S. aureus growth (240 minutes) over baseline
(horizontal line). The single asterisk indicates a significant increase
(p,0.05) in growth over baseline. The double asterisks indicates a
significant (p,0.05) reduction in S. aureus growth in the presence of
platelets that were treated with or without Taxol or Nocodazole.
(TIF)
Figure S5 LPS does not induce platelets to release b-
defensin 1. hBD-1 protein in lysates and supernatants from
platelets that were stimulated with LPS (100 ng/ml) for 30
minutes. The bars represent the mean6SEM of three independent
experiments.
(EPS)
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